Trials / Suspended
SuspendedNCT04746131
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMM0306 | IMM0306 is an bi-specific antibody |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
- First posted
- 2021-02-09
- Last updated
- 2022-09-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04746131. Inclusion in this directory is not an endorsement.